From the collective departure of Pfizer executives to see the impact of national collection on generic drug companies

As China's healthcare reform continues to deepen, continuous improvement in all aspects from R&D, production, distribution and marketing has helped China's pharmaceutical sector to rapidly converge with international standards and promote the transformation and upgrading of Chinese pharmaceutical enterprises. In the past, foreign pharmaceutical companies expired patent original research and development drugs in the country has been enjoying the patent drug level treatment, pricing and policies are better than domestic drugs. And domestic pharmaceutical enterprises are only in the rough and tumble operation, without the need for precise strategy can also be for the success. But with the industry in the policy changes, local pharmaceutical enterprises gradually explore the advancement and quietly rise.

At present, major companies are actively expanding BD business or implementing overseas mergers and acquisitions to seek access to broader overseas resources, which in turn enrich their own product lines of the company. The main reason is that foreign R&D institutions and R&D-based companies have developed earlier, but do not have the ability to expand globally, so they are seeking partners in major markets to broaden their product sales channels. Joint ventures with foreign companies to expand international markets. In the future, with India's experience and channels in the global generic drug field, Chinese companies will be able to understand the rules of international competition and enter the international market more quickly. But this part also needs to be fully justified, in the past several Chinese pharmaceutical companies in joint ventures with pharmaceutical giants, the desire to enter the international market has not been achieved.